Today: 19 April 2026
Sembcorp Industries share price slips in Singapore as Micron deal meets Alinta questions ahead of Feb 25 results
2 February 2026
1 min read

Sembcorp Industries share price slips in Singapore as Micron deal meets Alinta questions ahead of Feb 25 results

Singapore, Feb 2, 2026, 15:38 SGT — Regular session

  • Sembcorp shares slipped in mid-afternoon trading following a turbulent week driven by deal rumors
  • Investors are balancing Micron’s power-supply expansion with the looming Alinta acquisition process
  • Focus shifts to upcoming regulatory milestones and Sembcorp’s FY2025 earnings set for later this month

Sembcorp Industries Ltd (SGX:U96) shares dipped 0.8% to S$5.98 by mid-afternoon Monday, after moving within a range of S$5.96 to S$6.09. The stock had climbed 3.6% on Jan. 29 but dropped 1.6% to close Friday at S$6.03.

This shift matters as investors juggle two narratives simultaneously: a long-term power contract extension linked to semiconductor demand, and a major overseas acquisition awaiting regulatory approval. Earnings are the next key milestone, with the report looming close.

The wider environment hasn’t been kind. Risk appetite waned across Asia following sharp declines in precious metals and slipping oil prices, unsettling markets, Reuters reported.

On Jan. 28, Sembcorp announced it had reached key terms to expand an 18-year power purchase agreement (PPA) with a Micron Technology unit, boosting supply by 150 megawatts while maintaining the contract through 2041. The company said this extension is not expected to materially affect FY2026 earnings per share or net tangible assets per share, which excludes intangible assets from the balance sheet.

Alinta Energy is another key factor. A Singapore Exchange filing revealed shareholders greenlit the acquisition at a Jan. 30 extraordinary general meeting, with 99.76% voting yes. Still, final approval hinges on other conditions. According to Sembcorp’s website, the deal is expected to close in the first half of 2026, pending regulatory sign-off and usual closing steps. The Business Times noted the transaction includes a coal-fired plant that supplies roughly 20% of Victoria’s electricity.

Earlier, Citi Research analyst Luis Hilado called the acquisition “half-full” and “half-empty,” highlighting possible earnings gains but also setbacks to decarbonisation goals. The Business Times

Sembcorp has kept expectations tempered regarding near-term gains from the Micron expansion, possibly prompting investors to sell off quickly. Now, focus shifts to the earnings outlook and any details on execution risk tied to the acquisition as the next key drivers.

Still, it can backfire. Delays in regulatory approval, tighter funding conditions, or increased scrutiny on coal-related emissions might push the company’s upcoming results and guidance higher than expected.

Sembcorp plans to publish its FY2025 financial results on Feb. 25 before the market opens, according to a Singapore Exchange filing. Investors are keen on any guidance the company provides, especially updates on the Alinta approval timeline.

Stock Market Today

  • 2 TSX Stocks Under $100 with Strong Upside Potential
    April 18, 2026, 9:56 PM EDT. CES Energy (TSX:CEU) and Bird Construction are two TSX-listed stocks priced below $100 that offer significant growth potential. CES Energy provides consumable chemical solutions to oil and gas producers, benefiting from rising service intensity and demand for advanced chemical treatments. Despite softer drilling activity, CES's revenue growth remains robust, supported by its asset-light model and strategic acquisitions. Macro trends like growing global energy demand and LNG infrastructure expansion further boost its outlook. Bird Construction, also trading under $100, stands out for its presence in the construction sector, which benefits from infrastructure spending and urban development. Both companies show disciplined capital allocation and resilient revenue drivers, making them attractive for investors seeking accessible entry points and potential capital appreciation on the TSX.

Latest article

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
OCBC stock price drops in Singapore as metals rout jolts markets; earnings next
Previous Story

OCBC stock price drops in Singapore as metals rout jolts markets; earnings next

HSBC share price near record highs: what to watch before the BoE and February results
Next Story

HSBC share price near record highs: what to watch before the BoE and February results

Go toTop